Cholesterol Test (Lipid Profile) in Johor Bahru

Most people read a lipid profile from the top down, and the top line is total cholesterol. It is the number patients quote to each other, and it carries the least information on the report. The reason is arithmetic. Total cholesterol is the sum of the cholesterol carried in every lipoprotein fraction in your blood, and those fractions do not do the same thing. Some deposit cholesterol into artery walls. One is associated with the opposite. Adding them together averages out the very distinction that matters clinically. Consider two people who both walk in with a total cholesterol of 6.0 mmol/L. In the first, HDL is 2.1 and LDL is 3.3. In the second, HDL is 0.9 and LDL is 4.6. The single number is identical; the clinical position is not remotely the same, and the second person needs attention the first may not. On the total alone we would treat two different problems as one. It works in the other direction too. A total cholesterol that looks reassuringly ordinary can conceal a low HDL and raised triglycerides, a common pattern in people carrying weight around the middle, in insulin resistance and in diabetes. Nothing on the top line flags it. So do not anchor on the total. It is a rough screening figure with some value in flagging extremes, and a total above roughly 7.5 mmol/L is worth pursuing on its own. But for deciding what happens next in one individual, the useful information is in the lines beneath it.

LDL cholesterol is the number that does the damage, and it is the primary target of treatment. Understanding why means understanding what happens inside an artery, because the process is slow, silent, and well advanced before anyone feels anything. LDL particles circulating in the blood cross the inner lining of an artery into the wall itself, and the more particles there are and the longer they are there, the more accumulate. Inside the wall they undergo chemical modification, principally oxidation, and the immune system responds to them as it would to something foreign. White cells move in, engulf the modified LDL, become bloated foam cells and die there. That debris, with the cholesterol released from it, forms the fatty core of a plaque, which the body walls off with a fibrous cap. Two things can then happen. The plaque can grow gradually and narrow the vessel, which produces angina on exertion or claudication in the legs. Or the fibrous cap can rupture. Blood meets the thrombogenic core, a clot forms within minutes, and the artery is blocked. That is a heart attack or an ischaemic stroke, and it can occur in a plaque that never narrowed the artery enough to cause a single symptom beforehand. This is why the process is treacherous. Plaque accumulates from early adult life onward, entirely painlessly, and the first indication that it exists is frequently the event itself. There are no symptoms of high cholesterol, and no feeling of thick blood. People who say they can tell when their cholesterol is up are describing something else. The practical consequence is that lower LDL, sustained over years, means less plaque and fewer events, and in people at higher risk that benefit is real and proportional. It does not follow that everyone needs the lowest possible figure, which is the argument taken up below.

HDL cholesterol is the fraction associated with lower cardiovascular risk. Higher levels track with fewer events in large observational studies, and a low HDL is one of the features that makes a profile look unfavourable. Broadly, below about 1.0 mmol/L in men and 1.2 mmol/L in women counts as low. But an honest word is owed, because the popular framing of HDL as good cholesterol you should try to raise has not survived testing. Several classes of drug raise HDL substantially, and in large trials the higher HDL did not translate into fewer heart attacks or strokes. Some of those trials were stopped for lack of benefit or for harm. The evidence supports treating HDL as a marker of risk rather than a target. A low HDL tells us something useful, often that you are inactive, carrying excess weight, smoking or insulin resistant. It identifies people who need attention. It is not itself the thing to fix with a tablet. Triglycerides are the most volatile number on the report. They rise after a meal and markedly after alcohol, so a result taken the morning after a heavy dinner is not representative. They rise with uncontrolled diabetes, hypothyroidism, kidney disease, and with medications including steroids, some diuretics and oestrogens. A raised triglyceride is a prompt to look for a cause rather than a finding to accept. Very high triglycerides carry a second and quite separate danger. Above roughly 10 mmol/L the risk of acute pancreatitis rises, and higher still it becomes substantial. That is an inflammatory emergency of the pancreas with nothing to do with atherosclerosis, and it changes the urgency entirely. Markedly raised triglycerides are treated to prevent pancreatitis in their own right.

Non-HDL cholesterol deserves far more attention than it gets. It is either on the report or worked out in a second, and it is often a better guide than LDL. The calculation is total cholesterol minus HDL cholesterol. What that leaves is the cholesterol carried in every atherogenic particle in the blood, not just LDL: very low density lipoprotein, intermediate density and remnant particles, and lipoprotein(a). All of these deposit into artery walls. LDL is the largest contributor but not the only one, and in some people the others matter a great deal. Two groups are better assessed with non-HDL. Anyone with raised triglycerides, because the calculated LDL becomes unreliable as triglycerides climb and because remnant particles are atherogenic and invisible in the LDL figure. And people with diabetes or metabolic syndrome, in whom that exact pattern is common. In both, a reassuring LDL can sit alongside a genuinely unfavourable non-HDL. Non-HDL has one further virtue: because it does not depend on the calculated LDL, it holds up in a non-fasting sample. As a rough rule, the non-HDL target sits about 0.8 mmol/L above the corresponding LDL target. Which brings us to fasting. A non-fasting lipid profile is now regarded as acceptable for routine screening and risk assessment in most people. You spend most of your waking life in a non-fasting state, so the sample reflects what your arteries are actually exposed to, and it removes the barrier of a dawn appointment on an empty stomach. Fasting is still preferred in specific situations: when triglycerides are known to be markedly raised, when a precisely calculated LDL is needed, and when a triglyceride problem is being monitored over time. Fasting in practice means eight to twelve hours with no food or drink other than plain water, taking your usual medicines unless told otherwise. The doctor arranging your test will tell you which applies rather than leave you to guess.

Patients want a single figure to aim at. It is a reasonable thing to want and there is no honest way to supply it, because the target depends on how much cardiovascular risk you carry overall. An LDL of 3.4 mmol/L in a healthy 32-year-old with normal blood pressure, no diabetes, no smoking history and no family history of early heart disease is a number to watch and address through how she eats and moves. The identical 3.4 mmol/L in a man who had a heart attack two years ago is a treatment failure. Same arithmetic, different meaning, because his arteries have already demonstrated what they will do. Risk assessment puts the numbers into that context. It combines age, sex, smoking status, blood pressure, diabetes and how long it has been present, kidney function, family history of premature cardiovascular disease, and above all whether you already have established vascular disease. Scoring tools exist, though they perform imperfectly across populations and are a guide to a conversation rather than a verdict. Broadly, risk sorts people into bands. Someone at low risk is generally aiming for an LDL below about 3.0 mmol/L through lifestyle. At moderate risk, below 2.6. High risk, which includes most people with long-standing diabetes, chronic kidney disease or a very raised single risk factor, brings the target towards 1.8 mmol/L or lower. Very high risk, meaning established disease such as a previous heart attack, stroke, stent, bypass or symptomatic peripheral arterial disease, brings it towards 1.4 mmol/L, with a reduction of at least half from baseline expected. So two people can be handed the same report and told different things, and neither has had wrong advice. It also means a result flagged as normal against a laboratory reference range may be well above the target that applies to you, because those ranges are population ranges rather than personal ones. We run blood tests on site, so the profile and the discussion of what it means happen in the same place. Call +60 7-251 1162 or WhatsApp +60 17-500 7205 to arrange it, and ask about test costs while you are on the line.

Familial hypercholesterolaemia is an inherited disorder that produces a very high LDL cholesterol from birth. It is not rare, affecting something in the order of one in every two to three hundred people, which means any busy clinic sees it regularly. It is under-diagnosed rather than uncommon, and most people who have it do not know. The mechanism is a fault in the body's ability to clear LDL, usually in the LDL receptor. The consequence is lifelong exposure to a high LDL, and because plaque accumulation depends on how high the level is and for how long, the arterial damage starts in childhood. Untreated, it causes heart attacks decades early, sometimes in the thirties and forties. The clues that should prompt testing are worth knowing. A very high LDL, particularly above about 4.9 mmol/L in an adult and lower than that in a child. A family history of heart attack, angina, bypass surgery or sudden cardiac death before roughly 55 in male relatives and 65 in female relatives. Tendon xanthomata, firm nodular thickenings of the Achilles tendon or the tendons on the backs of the hands, close to diagnostic when present. Corneal arcus, a pale ring at the edge of the iris, unremarkable in the elderly but significant under about 45. The crucial feature is that this is a family diagnosis, not an individual one. Each first-degree relative has roughly a one in two chance of carrying it, so when one case is identified the parents, siblings and children should all be tested. Children included, because treatment started early prevents the damage rather than repairing it. This is the single strongest reason to take family history seriously. If a parent, sibling or grandparent had a heart attack young, say so, and say so before anyone has to ask.

Dietary advice fails here for a predictable reason. It is written as prohibition, demands home cooking three times a day, and treats the food people actually eat as the enemy. Nobody sustains that. What works is a change in frequency and portion, kept up for years rather than weeks. The saturated fat in Malaysian eating comes from a few identifiable places. Santan, in curries, laksa, rendang, nasi lemak and a long list of kuih and desserts. Deep-fried food, from goreng pisang to fried chicken to keropok. Palm oil in cooking and, in its hardened form, in packaged biscuits, creamers and snacks. Ghee and butter in roti canai, murtabak and pastries. Sweetened condensed milk in teh tarik, kopi and cendol raises triglycerides rather than LDL, but it raises them reliably. Processed and red meat round out the list. Now the realistic version. Nasi lemak is not the problem; daily nasi lemak is. Move it to a weekend thing. Take half a portion of the santan gravy, or ask for it on the side. Share a fried dish rather than ordering your own. Choose the grilled option some of the time, not every time: ikan bakar instead of ikan goreng twice a week is a genuine change. Ask for kurang manis until it stops tasting odd. At home, thinning the santan works better than banning it. What you add matters as much, because subtraction alone tends not to last. Vegetables at every meal, which Malaysian cooking makes easy. Fruit in place of a sweet snack. Oily fish such as sardines, mackerel or kembung twice a week. A handful of unsalted nuts. Oats, wholegrains and brown rice at least some of the time. Legumes, dhal and beans, which lower cholesterol in their own right through soluble fibre. Eating out is normal here and it is not going to stop. A plan assuming you cook every meal fails within a fortnight; one built around what you order at the stall does not. The rest comes without moralising. Aim for around 150 minutes of moderate activity a week, which can be walking. Losing even five to ten per cent of body weight improves triglycerides and HDL measurably. Alcohol raises triglycerides directly, so if triglycerides are your problem that is one of the fastest levers available. Stopping smoking does more for your cardiovascular risk than any cholesterol number will.

More people refuse statins because of something they read than because of anything that happened to them, so the concerns deserve going through properly rather than dismissing. Statins are among the best-evidenced medicines in existence, tested in very large randomised trials across many populations over decades, and they reduce heart attacks, strokes and cardiovascular death in people at raised risk. Muscle aches are the commonest complaint and the main reason people stop. They are real, and dismissing them is both unkind and counterproductive. The trial data shows that when neither patient nor doctor knows who is taking the statin, muscle symptoms occur at close to the same rate in both groups, whereas in open use they are reported far more often. Expectation contributes, though that does not make anyone's aching legs imaginary. Either way the response is the same: stop briefly to confirm the link, then reduce the dose, switch statin, or dose on alternate days. Most people who believe they cannot tolerate statins can tolerate one of them, and abandoning treatment should be the last option. Rhabdomyolysis, severe muscle breakdown that can damage the kidneys, is genuinely rare, but know the warning signs: severe generalised muscle pain and weakness, particularly with dark tea-coloured urine and feeling unwell. That means stopping the tablet and being seen the same day. Liver injury is a common fear and a rare event. Statins can raise liver enzymes, usually mildly and often settling on their own. Practice has moved away from routine repeated testing towards checking before starting and again if there is a clinical reason, and only a substantial persistent rise prompts stopping. There is a small increase in the chance of being diagnosed with type 2 diabetes, mostly in people who already have features of the metabolic syndrome and were heading that way. It is real, but in proportion: among people at meaningful cardiovascular risk, the heart attacks and strokes prevented substantially outweigh the extra diabetes diagnoses, and diabetes is itself treatable. Statins do not damage the kidneys. That belief is widespread and unsupported. Will you be on it for life? Usually, because the drug treats an ongoing process rather than curing it. Stop it and cholesterol returns to roughly where it was within weeks. It is closer to blood pressure treatment than to a course of antibiotics. Doses are reviewed and sometimes reduced, but that is a decision to make with your doctor rather than at home. Can lifestyle replace medication? Sometimes, in someone at lower risk with a modestly raised LDL and real room to change. Often it reduces the dose needed rather than removing it. In familial hypercholesterolaemia it cannot, because no diet corrects a clearance defect. Lifestyle and medication are not competitors. One thing overrides all of the above. Chest pain or tightness, sudden breathlessness, or stroke symptoms such as the face drooping on one side, weakness in one arm, or slurred speech mean calling 999 or going straight to the nearest emergency department. Do not wait for a clinic appointment and do not drive yourself. For everything that is not an emergency, we are at No. 62 Jalan Kiambang, Taman Bunga Raya, 81700 Masai, Johor, open Monday to Thursday and Saturday 9AM to 9PM, Friday 9AM to 3PM and Sunday 9AM to 1PM, and you can book at movo-x.com/kiosk/muhibbah. Dr. Prabagaran Kanapathy and Dr. Kirubah Sai Patnaik see patients here, and the clinic is PEKA B40 registered, which covers screening for eligible Malaysians aged 40 and above. This page is general information for a Malaysian audience and does not replace a consultation about your own results.